TY  - CHAP
M1  - Book, Section
TI  - Cancer Treatment and Chemotherapy
A1  - Shord, Stacy S.
A1  - Cordes, Lisa M.
A2  - DiPiro, Joseph T.
A2  - Talbert, Robert L.
A2  - Yee, Gary C.
A2  - Matzke, Gary R.
A2  - Wells, Barbara G.
A2  - Posey, L. Michael
PY  - 2017
T2  - Pharmacotherapy: A Pathophysiologic Approach, 10e
AB  - Content  UpdateAugust  28,  2019Erdafitnib  Approved  for  FGFR  Mutated  Bladder  Cancers:  Erdafitnib  (Balversa®)  is  the  first  FGFR  inhibitor  approved  by  the  FDA  and  is  indicated  for  adults  with  FGFR3  or  FGFR2  mutations  in  locally  advanced  and  unresectable  or  metastatic  bladder  cancer  who  have  progressed  on  prior  therapy.  FGFR  mutations  are  common,  occurring  in  up  to  60%  of  bladder  cancers.  In  an  open-label,  multicenter,  Phase  II  trial,  the  median  progression  free  survival  was  5.5  months  (95%  CI,  4.2-6.0).  The  overall  response  rate  to  erdafitnib  was  40%.  The  most  common  adverse  effects  were  hyperphosphatemia,  stomatitis  and  diarrhea.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2024/04/18
UR  - accesspharmacy.mhmedical.com/content.aspx?aid=1168069938
ER  -